Stock AnalizHerbalife Ltd. HLF
Other Pharmaceuticals · IPO 2004 · data as of November 13, 2026
Herbalife Ltd. (HLF) is a healthcare company listed in the US with a market value of about $1.7B. In the twelve months to September 30, 2026 it had revenue of $5.3B and net income of $180M, a net margin of 3.4%.
Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is value (4/5); the weakest is future growth (1/5).
Key numbers: a P/E of 9.4, a price to free cash flow of 5.0, 5-year revenue growth of -2% a year, a 5-year average ROIC of 24%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 86% above the current price.
Score: 1.8 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Profit margin improving
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- Positive free cash flow
Checks not passed
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- ROE above 15%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.3B | $5.0B | $5.0B | $5.1B | $5.2B | $5.8B | $5.5B | $4.9B | $4.9B | $4.4B | $4.5B |
| Net income | $180M | $228M | $254M | $142M | $321M | $447M | $373M | $311M | $297M | $214M | $260M |
| Free cash flow | $337M | $253M | $163M | $222M | $196M | $309M | $517M | $351M | $564M | $495M | $224M |
| EPS (diluted) | $1.69 | $2.20 | $2.50 | $1.42 | $3.23 | $4.13 | $2.77 | $2.20 | $1.98 | $1.29 | $1.51 |
| Net margin | 3.4% | 4.5% | 5.1% | 2.8% | 6.2% | 7.7% | 6.7% | 6.4% | 6.1% | 4.8% | 5.8% |
| ROIC | — | 23.9% | 18.3% | 14.6% | 24.9% | 36.2% | 25.5% | 24.2% | 25.2% | 25.2% | 19.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $17.33, 9% above the current price; targets range from $10.00 to $25.00; the consensus rating is “Buy”; expected EPS is $2.35 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Herbalife’s P/E ratio?
About 9.4, based on the last twelve months of diluted earnings per share (forward P/E about 5.7).
Is Herbalife stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 86% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Herbalife pay a dividend?
Not currently.
Is Herbalife a good stock to buy?
We do not give buy or sell advice. Herbalife scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.